Allergan buys ww rights to bladder drug delivery technology


Allergan (AGN +1.1%) acquires the worldwide rights to Taris Biomedicals' lead program, LIRIS, currently in Phase 2 clinical trials for the treatment of  interstitial cystitis/bladder pain syndrome. LIRIS' value proposition is the ability to continuously deliver lidocaine to the bladder over an extended period. It accomplishes this by incorporating three proven drug delivery strategies: osmotic delivery, shape memory technology and implant retention.

Under the terms of the agreement, Allergan will pay Taris $67.5M in cash upfront and up to $295M in development milestone payments and up to $225M in commercial milestone payments.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs